At the ESGCT meeting in Seville, Intellia Therapeutics provided clinical updates on its in vivo CRISPR and LNP delivery programs, highlighting NTLA‑2002 (lonvo‑z) for hereditary angioedema (HAE). Company CSO Birgit Schultes reported sustained reductions in kallikrein activity to under 60% lasting beyond two years and no serious adverse events beyond transient liver enzyme elevations. Intellia has treated over 350 patients across its in vivo programs and shared published NEJM papers describing safety and efficacy for its earlier programs. Schultes emphasized LNP delivery advantages—transient expression and redosing capability—and noted rigorous nonclinical work to minimize germline exposure. The update underscored a strategic pivot: the HAE program now appears to outpace the ATTR program in clinical momentum. Intellia’s progress matters for the gene‑editing field as regulators and investors watch in vivo LNP‑based CRISPR approaches transition from proofs‑of‑concept to durable clinical benefit.